Aclarubicin Recruiting Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) / Relapsed Leukemia Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03181815Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
NCT03045627Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients